Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo

Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo

RationaleThe development of inhibitors of microsomal prostaglandin (PG)E2 synthase-1 (mPGES-1) was driven by the promise of attaining antiinflammatory agents with a safe cardiovascular profile because of the possible diversion of the accumulated substrate, PGH2, towards prostacyclin (PGI2).Objective...

Full description

Bibliographic Details
Main Authors: Luigia Di Francesco, Annalisa Bruno, Emanuela Ricciotti, Stefania Tacconelli, Melania Dovizio, Paloma Guillem-Llobat, Maria Alessandra Alisi, Beatrice Garrone, Isabella Coletta, Giorgina Mangano, Claudio Milanese, Garret A. FitzGerald, Paola Patrignani
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Pharmacology
Subjects:
microsomal prostaglandin E2 synthase-1 inhibitors
microsomal prostaglandin E2 synthase-1
cyclooxygenases-2
whole blood
prostaglandin E2
TXB2
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00374/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00374/full

Similar Items